title: Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate Cancer: Relating 33 Years of Patient Clinical Care.
authors.affiliation: International Strategic Cancer Alliance, Jacksonville, Oregon.
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Strum
authors.affiliation: Prostate Oncology Specialists, Marina del Rey, California.
authors.forename: Mark C
authors.initials: MC
authors.lastname: Scholz
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects; D000728:Androgens / Q000378:metabolism*; D000813:Anilides / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions / Q000503:physiopathology*; D005485:Flutamide / Q000009:adverse effects; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects; D007989:Libido / Q000187:drug effects; D008297:Male; D006278:Medicare; D009362:Neoplasm Metastasis; D009570:Nitriles / Q000009:adverse effects; D010413:Penis / Q000187:drug effects / Q000503:physiopathology; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D014105:Tosyl Compounds / Q000009:adverse effects; D014481:United States
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D000813:Anilides; D009570:Nitriles; D014105:Tosyl Compounds; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; C053541:bicalutamide; D016729:Leuprolide